FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2563 June 16, 2005 Number 24 Next

PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Okie, S.

What Ails the FDA? . On page 1064, in the last paragraph in the left-hand column, line 3 should have read, "For new molecular entities (drugs whose active ingredient has never before been approved in the United States) that were given a `priority review,'" rather than "For drugs given a `priority review,'" as printed. In the same paragraph, lines 7 and 8 should have read, "For new molecular entities given a `standard review,'" rather than "For drugs given a `standard review,'" as printed. In the graph on page 1065, the first entry in the key should have read, "All new molecular entities," rather than "All new drugs," as printed. The title of the graph should have read, "Median Total Time to FDA Approval for New Molecular Entities," rather than "for New Drug Applications," as printed. The second sentence of the legend should have read, "The number at the bottom of each bar is the number of new molecular entities approved," rather than "the number of drugs reviewed," as printed. We regret the errors.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.